Join
Live feed
·
PRReleasevia Quantisnow
Instil Bio Inc. logo

Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

ByQuantisnow·Wall Street's wire, on your screen.
TIL· Instil Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TIL (Instil Bio Inc.) and more on Quantisnow.